ALTUVOCT (efanesoctocog alfa) - Haemophilia A
Opinions on drugs -
Posted on
Dec 05 2024
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement in the MA indication: “Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ALTUVOCT can be used for all age groups.”
Clinical Benefit
Substantial |
The Committee deems that the clinical benefit of ALTUVOCT 250 IU, 500 IU, 750 IU, 1,000 IU, 2,000 IU, 3,000 IU and 4,000 IU (efanesoctocog alfa) powder and solvent for solution for injection is substantial in the MA indication. |
Clinical Added Value
no clinical added value |
the Committee deems that ALTUVOCT 250 IU, 500 IU, 750 IU, 1,000 IU, 2,000 IU, 3,000 IU and 4,000 IU (efanesoctocog alfa) powder and solvent for solution for injection provides no clinical added va |
Documents
English version
Contact Us
Évaluation des médicaments